These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24164171)

  • 1. Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
    Norrby K
    APMIS; 2014 Jul; 122(7):565-79. PubMed ID: 24164171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic therapy: chemotherapy revisited.
    Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
    Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
    Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
    Ciccolini J; Barbolosi D; Meille C; Lombard A; Serdjebi C; Giacometti S; Padovani L; Pasquier E; André N
    Cancer Res; 2017 Sep; 77(17):4723-4733. PubMed ID: 28655786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A.
    Albertsson P; Lennernäs B; Norrby K
    Acta Oncol; 2006; 45(2):144-55. PubMed ID: 16546859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
    Hida K; Kikuchi H; Maishi N; Hida Y
    Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
    Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
    Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
    Murray A; Little SJ; Stanley P; Maraveyas A; Cawkwell L
    Oncol Rep; 2010 Oct; 24(4):1049-58. PubMed ID: 20811688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.
    Naganuma Y; Choijamts B; Shirota K; Nakajima K; Ogata S; Miyamoto S; Kawarabayashi T; Emoto M
    Cancer Sci; 2011 Aug; 102(8):1545-52. PubMed ID: 21631643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to metronomic chemotherapy and ways to overcome it.
    Riesco-Martinez M; Parra K; Saluja R; Francia G; Emmenegger U
    Cancer Lett; 2017 Aug; 400():311-318. PubMed ID: 28259819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
    Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
    Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.